Press

Field Trip Health & Wellness Provides Business Update and Reports Fiscal Third Quarter 2023 Results

Feb 28 • 3 min read

Field Trip Health & Wellness Ltd. (TSXV: FTHW | OTCQB: FTHWF), a global leader in the delivery of psychedelic therapies, provided a business update today and reported its fiscal third quarter 2023 results for the three and nine month periods ended December 31, 2022. All results are reported in accordance with International Financial Reporting Standards…

Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board

Feb 28 • 3 min read

FSD Pharma Inc. (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that iconic entrepreneur Kevin Harrington has joined the Company’s Advisory Board. Mr. Harrington is world renowned as the…

Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program

Feb 28 • 5 min read

Cybin Inc. (NEO:CYBN | NYSE American:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced significant progress updates for its two lead clinical development programs: CYB003, its proprietary deuterated psilocybin analog for the potential treatment of Major Depressive Disorder and CYB004, its proprietary deuterated N,N-dimethyltryptamine molecule being developed for the potential treatment of Generalized Anxiety…

Enosis Therapeutics announces its response to Australian TGA decision, Plans to Present at SXSW 2023

Feb 28 • 4 min read

Enosis Therapeutics, a medical technology and psychedelic research company that leverages virtual reality (VR) to optimize the psychotherapeutic experience for both the patient and the therapist, provided an update today on its offer to Australian therapists in response to the the recent announcement from the Therapeutic Goods Administration, and it’s plans to participate and present at SXSW 2023. Therapeutic…

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Feb 28 • 12 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2022 and gave an update on recent progress across its business. “During this past quarter, we commenced our COMP360 phase 3 pivotal program…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441